This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Czyz M , Toma M , Gajos-Michniewicz A , Majchrzak K , Hoser G , Szemraj J , Nieborowska-Skorska M , Cheng P , Gritsyuk D , Levesque M , Dummer R , Sliwinski T , Skorski T
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
Oncotarget. 2016 Nov 15;7(46) :75551-75560
PMID: 27705909 PMCID: PMC5342760
AbstractCancer including melanoma may be ''addicted" to double strand break (DSB) repair and targeting this process could sensitize them to the lethal effect of DNA damage. PARP1 exerts an important impact on DSB repair as it binds to both single- and double- strand breaks. PARP1 inhibitors might be highly effective drugs triggering synthetic lethality in patients whose tumors have germline or somatic defects in DNA repair genes. We hypothesized that PARP1-dependent synthetic lethality could be induced in melanoma cells displaying downregulation of DSB repair genes. We observed that PARP1 inhibitor olaparib sensitized melanomas with reduced expression of DNA ligase 4 (LIG4) to an alkylatimg agent dacarbazine (DTIC) treatment in vitro, while normal melanocytes remained intact. PARP1 inhibition caused accumulation of DSBs, which was associated with apoptosis in LIG4 deficient melanoma cells. Our hypothesis that olaparib is synthetic lethal with LIG4 deficiency in melanoma cells was supported by selective anti-tumor effects of olaparib used either alone or in combination with dacarbazine (DTIC) in LIG4 deficient, but not LIG4 proficient cells. In addition, olaparib combined with DTIC inhibited the growth of LIG4 deficient human melanoma xenografts. This work for the first time demonstrates the effectiveness of a combination of PARP1 inhibitor olaparib and alkylating agent DTIC for treating LIG4 deficient melanomas. In addition, analysis of the TCGA and transcriptome microarray databases revealed numerous individual melanoma samples potentially displaying specific defects in DSB repair pathways, which may predispose them to synthetic lethality triggered by PARP1 inhibitor combined with a cytotoxic drug.
Notes1949-2553 Czyz, Malgorzata Toma, Monika Gajos-Michniewicz, Anna Majchrzak, Kinga Hoser, Grazyna Szemraj, Janusz Nieborowska-Skorska, Margaret Cheng, Phil Gritsyuk, Daniel Levesque, Mitchell Dummer, Reinhard Sliwinski, Tomasz Skorski, Tomasz P30 CA006927/CA/NCI NIH HHS/United States R01 CA186238/CA/NCI NIH HHS/United States Journal Article United States Oncotarget. 2016 Nov 15;7(46):75551-75560. doi: 10.18632/oncotarget.12270.